Mermade

**Product and the concrete problem it solves.** Mermade is addressing a quiet but fundamental bottleneck in biomanufacturing: cell-based production consumes expensive growth media, and that media becomes contaminated with waste metabolites that can inhibit further growth. In cultivated seafood and other cellular-agriculture processes, the medium is not a minor consumable; it is a recurring operating cost, a water burden, and a source of wastewater and upstream environmental impact. Mermade began publicly as a company developing cultivated scallops, but its current website positions the business more broadly as a media-recycling platform for biomanufacturing. The product thesis is that manufacturers should recover value from partially used media instead of disposing of it and replacing it entirely. That can change the economics of cell-based seafood, cell therapies, diagnostics, and other biological production workflows without requiring every customer to redesign its target cell line or final product. The company’s current message emphasizes a recovery process that extracts waste metabolites and reclaims nutrients, with reported potential for up to 80% lower greenhouse-gas emissions, up to 70% less purified-water use, and up to 80% less wastewater discharge. Those figures are company-stated potential, not independently verified production results, but they define a specific commercial problem and a measurable value proposition.

**Core technology and how it actually works.** Mermade describes its platform as a patented microalgae-based method that selectively removes waste metabolites from partially used media while retaining other components needed for cell growth. The older cultivated-seafood description provides the clearest public explanation of the biological loop: cells release waste into the growth medium; microalgae consume or transform that waste and generate new biomass; the recovered biological material is then used to restore useful nutrients for the next cell-culture cycle. Mermade called this approach cytoponics in its earlier foodtech communications and later refers to the system as media recycling, including an ARM, or Algae Recycled Media, platform in a 2025 collaboration notice. The distinction from ordinary filtration matters. The company is not merely removing particles from wastewater; it is trying to preserve the expensive biological components of the medium while selectively managing inhibitory metabolites and creating a reusable nutrient stream. The official site claims the process is clean, sustainable, and cost-efficient, but it does not disclose the exact algal species, metabolite-removal selectivity, media composition, sterilization protocol, batch or continuous-flow parameters, recovery yield, or intellectual-property number. The public technical description supports a plausible circular bioprocess architecture, while reproducibility across cell types, contamination control, regulatory acceptance, and performance at production scale remain open diligence questions.

**Market, customers, and go-to-market.** Mermade’s initial beachhead was cultivated seafood, with scallops selected as a comparatively tractable first product because a uniform shellfish target can be easier to develop than complex whole-cut meat. The current platform gives the company a wider B2B route: cell-agriculture producers, cell-therapy and regenerative-medicine manufacturers, diagnostic laboratories, fermentation companies, and bioprocess developers all buy or consume media and face waste-management constraints. The company is therefore better understood as a process-enabling supplier than as a consumer seafood brand. It can potentially sell a media-recycling unit or process module, license its technology to biomanufacturers, co-develop a validated workflow for a specific cell line, or supply recovered media and biological inputs through a service model. A 2025 collaboration opportunity says Mermade was seeking pilots to adapt ARM to new cell types and industries beyond cultured seafood, test larger production environments, and co-develop applications in diagnostics and biomanufacturing. That is an important sign of a platform expansion strategy, but it is also evidence that the work remained in validation and partnership formation rather than scaled commercial deployment. Public sources do not name paying customers, purchase orders, regulatory approvals, commercial plants, recurring revenue, or the economics of installing and operating the recycling process. Adoption will depend on proving that recovered media preserves cell performance and batch consistency while lowering total cost more than a customer’s existing media supplier and waste contractor.

**Traction, funding, and third-party validation.** Mermade was founded in 2021 and raised a disclosed $3.3 million Seed round from OurCrowd, Fall Line Capital, Sake Bosch, and other investors, according to contemporaneous reporting and ecosystem records. Startup Nation Central’s profile also records an Israel Innovation Authority grant in June 2022, while the Good Food Institute Israel report lists total funding of $4.8 million including the disclosed seed and additional support. IVC currently describes Mermade Ltd. as a 2026-updated, Seed-stage Hardware & Industrial company with five employees, a B2B model, and a Jerusalem address; the exact legal and financing status should be reconciled directly with the company because public databases do not agree on all timestamps or totals. The official site is active and has shifted its top-level positioning from a single cultivated-seafood product to media recycling for biomanufacturing, which is itself a meaningful strategic refinement. In February 2025, a SIIRD workshop listing described Mermade’s ARM system and sought collaboration to validate and scale it in larger production environments. These signals establish an operating Israeli biotech and a coherent development path, but not product-market fit. There is no public audited performance study, production-scale customer, validated greenhouse-gas accounting, regulatory approval for a food product, repeat financing, or disclosed revenue. The best reading is technically credible early-stage formation with a potentially valuable pivot from a final product to an enabling process layer.

**Founders and team background.** Mermade’s public team combines cell-biology and bioprocess expertise with commercial execution. Co-founder and CEO Daniel Einhorn is described by the company as having more than a decade of management and entrepreneurship experience, including business development, international partnerships, and B2B sales; he holds an MBA from Ben-Gurion University and a BA from the University of Haifa. Co-founder and COO Dr. Tomer Halevy is a cell-culture and bioprocess specialist who previously worked as a senior researcher at SuperMeat, where the company says he helped establish cell-line platforms, bioprocess design, and bench-to-50-liter continuous production. Co-founder and CTO Dr. Rotem Kadir is also a former SuperMeat project manager; Mermade says he founded tissue-culture and bioprocess laboratories, established primary cell lines, and later served as chief scientist at Soos and Ovo Technologies, developing analytical molecular assays. The team history is unusually relevant to the product because media recycling cannot be evaluated only as a wastewater process; it must preserve cell health, differentiation, yield, and repeatability. The founders’ cultivated-food experience explains the original scallop wedge and provides a practical understanding of media costs and cell-growth workflows. The limitations are scale and disclosure. IVC reports five employees, the wider team is not fully public, and there is no clear evidence of senior regulatory, manufacturing-quality, sales-engineering, or large-scale plant-operations capacity. The company must turn founder expertise into validated protocols that customers can run reliably outside its own laboratory.

**Competitive dynamics.** Mermade competes against several different substitutes rather than one identical product. Multus and other cultivated-meat media companies try to lower the cost of animal-free growth factors and media inputs, attacking the same cost bottleneck from the formulation side. CellRev and related companies pursue continuous or intensified cell-culture systems that improve productivity and can reduce media consumption through process design. Thermo Fisher Scientific, Cytiva, Merck, and other established life-science suppliers offer validated media, filtration, and bioprocess equipment with far greater distribution, quality systems, and customer trust. Cell-culture manufacturers can also choose to use single-use or conventional media and treat spent medium as a disposal cost, which is an unattractive but familiar incumbent approach. Mermade’s potential edge is the combination of selective metabolite removal, nutrient recovery, microalgae biology, and an original application in food-grade cell production. The platform could occupy a useful position between media suppliers and production operators if it enables reuse without harming cell growth or creating a new contamination and validation burden. Its proprietary process and accumulated cell-line compatibility data could become a moat, especially if the company proves the method across multiple biological systems. The edge is not established: microalgae can introduce biological variability, recovered media may behave differently from fresh media, and large customers may prefer a supplier with validated global quality infrastructure. Mermade must demonstrate repeatable savings, product consistency, sterility, regulatory compliance, and a deployment model that is simpler than purchasing more media.

**Defense, security, and resilience dual-use relevance.** Mermade’s strongest strategic relevance is resilience rather than direct defense. A domestic or allied capability to recycle biomanufacturing media can reduce dependence on imported inputs, lower purified-water requirements, and make distributed production of food, diagnostics, and potentially cell-based medical products more viable during supply-chain disruption. The original cultivated-seafood application also maps directly to food security: it aims to produce protein without relying on finite marine stocks, favorable coastal conditions, or a long conventional aquaculture chain, while the recycling layer attacks the cost and resource intensity that have limited alternative-protein scale. The same platform could have defense-adjacent value in resilient medical manufacturing, emergency bioprocessing, or remote facilities that need to use water and nutrients efficiently, although no defense program or military customer is public. This is not a weapons, cyber, or battlefield-autonomy company, and the database should not imply that it is. The dual-use flag is set conservatively around commercial and national-resilience applications: the technology can support both ordinary industrial biomanufacturing and strategic food, health, and supply-chain continuity. Key diligence should test whether the process works with medically or operationally important cell types, whether the recycled medium can be produced under high-assurance quality systems, and whether the energy, water, and waste benefits survive a full lifecycle analysis. Strategic value increases materially if Mermade proves a modular process usable in distributed or resource-constrained production, but current evidence remains platform potential rather than fielded resilience infrastructure.

**Growth stage, trajectory, and key diligence risks.** Mermade is early. Its 2021 founding, Seed financing, small team, active official website, and 2025 request for larger-scale pilots indicate a company still converting laboratory technology into a repeatable B2B process. The most promising trajectory is a deliberate shift from trying to commercialize one cultivated seafood product to selling a broadly useful media-recycling layer across biomanufacturing. That can expand the addressable market and reduce dependence on consumer acceptance of cultured scallops, but it also raises the technical burden because every cell type, medium, and production environment may require new validation. The key diligence questions are: (1) what patent family protects the microalgae process and who owns it; (2) how selectively does it remove inhibitory metabolites while retaining growth factors and nutrients; (3) what cell-growth, differentiation, contamination, sterility, and batch-consistency data exist across repeated cycles; (4) what savings remain after algae cultivation, separation, quality control, and facility integration; (5) whether the system works beyond laboratory or small-pilot scale; (6) which design partners are active and whether any have paid or signed a production agreement; (7) how food, medical, and industrial regulatory pathways differ; and (8) whether the five-person organization can support validation, manufacturing, sales, and quality assurance simultaneously. Risks include biological variability, contamination, regulatory delay, capital intensity, customer reluctance to modify validated processes, competition from cheaper media and growth-factor suppliers, and the possibility that large biomanufacturers internalize recycling. The upside is a strategic process technology that lowers resource intensity across resilient food and bio-production. The present evidence supports disciplined monitoring and technical diligence, not a conclusion that Mermade has reached commercial scale.